Anticancer activities of a benzimidazole compound through sirtuin inhibition in colorectal cancer
Yi Jer Tan1, Yeuan Ting Lee1, Keng Yoon Yeong1,2
1Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, 11800, Malaysia.
Aim:
This study aims to investigate the mode of action of a novel sirtuin inhibitor (BZD9L1) and its associated molecular pathways in colorectal cancer (CRC) cells.
Materials & Methods:
BZD9L1 was tested against metastatic CRC cell lines to evaluate cytotoxicity, cell cycle and apoptosis, senescence, apoptosis related genes and protein expressions, as well as effect against major cancer signaling pathways.
Results & Conclusion:
BZD9L1 reduced the viability, cell migration and colony forming ability of both HCT 116 and HT-29 metastatic CRC cell lines through apoptosis. BZD9L1 regulated major cancer pathways differently in CRC with different mutation profiles. BZD9L1 exhibited anticancer activities as a cytotoxic drug in CRC and as a promising therapeutic strategy in CRC treatment.
Insights
A novel sirtuin inhibitor, BZD9L1, effectively reduced colorectal cancer (CRC) cell viability and migration by inducing apoptosis. This compound shows promise as a colorectal cancer therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Colorectal cancer (CRC) remains a significant global health challenge.
- Targeted therapies are crucial for improving CRC treatment outcomes.
- Sirtuin inhibitors represent a potential new class of anticancer agents.
Purpose of the Study:
- To elucidate the mechanism of action of a novel sirtuin inhibitor, BZD9L1.
- To investigate the molecular pathways affected by BZD9L1 in colorectal cancer (CRC) cells.
- To evaluate the therapeutic potential of BZD9L1 in CRC.
Main Methods:
- Cytotoxicity assays were performed on metastatic CRC cell lines (HCT 116, HT-29).
- Cell cycle progression, apoptosis, and senescence were analyzed.
- Expression of apoptosis-related genes and proteins was assessed.
- Impact on major cancer signaling pathways was evaluated.
Main Results:
- BZD9L1 significantly reduced viability, migration, and colony formation in CRC cells.
- Apoptosis was identified as the primary mechanism of BZD9L1-induced cell death.
- BZD9L1 modulated cancer signaling pathways differently based on CRC mutation profiles.
- The inhibitor demonstrated cytotoxic effects against metastatic CRC cell lines.
Conclusions:
- BZD9L1 exhibits potent anticancer activities in colorectal cancer.
- BZD9L1 induces apoptosis and inhibits key cancer hallmarks in CRC cells.
- BZD9L1 represents a promising therapeutic strategy for colorectal cancer treatment.
Related Concept Videos
Inhibition of Cdk Activity
Feedback Inhibition
Molecules and Compounds
Organic Compounds
Elements and Compounds
Elements
Elements are classified as atomic or molecular based on the nature of their basic units. They are unique forms of matter with specific chemical and physical properties that cannot break down into smaller substances by ordinary chemical reactions. There...
Enzyme Inhibition


